好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

An Unusual Case of Anti-NMDAR Encephalitis with a Leukodystrophy-Like Presentation
Autoimmune Neurology
P10 - Poster Session 10 (5:00 PM-6:00 PM)
8-020
To describe a patient with anti-NMDA receptor (NMDAR) encephalitis and unusual clinical and MRI features
Anti-NMDAR encephalitis usually presents as subacute cognitive decline, psychiatric symptoms, and abnormal movements. Typical MRI features range from normal to involvement of temporal lobe. There are sporadic reported cases of diencephalon and rhombencephalon involvement. 
N/A

A 21-year-old male with a history of ADHD and anxiety, presented with 6 weeks of progressive fatigue and cognitive deficit. He had a recent trip to Florida where he developed afebrile upper respiratory infection which improved after an amoxicillin course. He then gradually developed slowed cognition and drowsiness followed by left sided brief muscle twitches, imbalance, and diplopia. His neurological exam showed decreased concentration, bradykinesia, and left sided dyskinesia. 

Enhanced brain MRI showed bilateral extensive confluent T2/FLAIR signal hyperintensity in basal ganglia, inferior frontal, and medial temporal, central midbrain and dorsal pons with mild edema. There was a mild nodular enhancement of the right putamen and vascular enhancement through both basal ganglia. 

Repetitive CSF studies showed a WBC count (22-32 cell/????), protein (56-66 mg/dL), oligoclonal bands (6-10), increased IgG index and synthesis rate. Whole body PET scan, testis ultrasound and CSF flow cytometry were unremarkable for malignancy. Hypermanganesemia, rheumatologic disorders, and Wilson’s disease were ruled out. Extensive CSF evaluation for infections, paraneoplastic and autoimmune encephalitis panels was unremarkable except for anti-NMDAR antibody. Encephalitis associated with basal ganglia involvement and/or rhombencephalitis were ruled out by negative serum and CSF antibodies against KELCH-like 11 protein, Ma/Ta, and GABA-A. He received seven plasma exchanges followed by steroids with symptomatic, MRI and CSF improvement. As he improved, his clinical picture evolved into pure psychiatric symptoms with auditory and visual hallucinations and obsessive-compulsive behavior. 

The diagnosis of anti-NMDAR encephalitis should be entertained albeit an uncommon presentation that might overlap with other autoimmune encephalitis. 
Authors/Disclosures
Rana K. Zabad, MD, FAAN (University of Nebraska Medical Center)
PRESENTER
Dr. Zabad has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer. Dr. Zabad has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Zabad has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Zabad has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celgene/BMS. Dr. Zabad has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme. Dr. Zabad has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck Serono. Dr. Zabad has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva Neurosciences. Dr. Zabad has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Zabad has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva. Dr. Zabad has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Zabad has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Genentech. Dr. Zabad has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BMS. The institution of Dr. Zabad has received research support from Adamas. The institution of Dr. Zabad has received research support from Biogen. The institution of Dr. Zabad has received research support from Novartis. The institution of Dr. Zabad has received research support from Sun Pharma. The institution of Dr. Zabad has received research support from Parexel & MedDay Pharmaceuticals.
Nasrin Rahimian, MD Dr. Rahimian has nothing to disclose.
Lakshman N. Arcot Jayagopal, MD (Nebraska Medical Center) Dr. Arcot Jayagopal has nothing to disclose.